SM22a is an adult smooth muscle-specific protein that is expressed in the smooth, cardiac, and skeletal muscle lineages during early embryogenesis before becoming restricted specifically to all vascular and visceral smooth muscle cells (SMC) in late fetal development and adulthood. We have used the SM22a gene as a marker to define the regulatory mechanisms that control muscle-specific gene expression in SMCs. Previously, we reported that the 445-base-pair promoter of SM22a was sufficient to direct transcription of a lacZ reporter gene in early cardiac and skeletal muscle cell lineages and in a subset of arterial SMCs, but not in venous nor visceral SMCs in transgenic mice. Here we describe two evolutionarily conserved CArG (CC(A/T) 6 GG) boxes in the SM22a promoter, both of which are essential for full promoter activity in cultured SMCs. In contrast, only the promoter-proximal CArG box is essential for specific expression in developing smooth, skeletal, and cardiac muscle lineages in transgenic mice. Both CArG boxes bind serum response factor (SRF), but SRF binding is not sufficient for SM22a promoter activity, since overexpression of SRF in the embryonal teratocarcinoma cell line F9, which normally expresses low levels of SRF, fails to activate the promoter. However, a chimeric protein in which SRF was fused to the transcription activation domain of the viral coactivator VP16 is able to activate the SM22a promoter in F9 cells. These results demonstrate the SM22a promoterproximal CArG box is a target for the regulatory programs that confer smooth, skeletal, and cardiac muscle specificity to the SM22a promoter and they suggest that SRF activates SM22a transcription in conjunction with additional regulatory factors that are cell type-restricted. ᭧ 1997 Academic Press pression (Owens, 1995). It is also unclear whether there are
INTRODUCTION
muscle gene regulatory programs that are shared by multiple muscle cell types or whether muscle genes that are ex-The three major muscle cell types, skeletal, cardiac, and pressed in multiple muscle cell types respond to myogenic smooth, express overlapping sets of muscle-specific genes regulatory programs unique to each muscle type. during development. Whereas several transcription factors SMCs are highly diverse with respect to their contractile, required for skeletal and cardiac muscle gene expression electrophysiological, and pharmacological properties as have been identified (Olson, 1993; Olson and Srivastava, well as embryonic origins (Schwartz et al., 1990; Akerlund, 1996) , little is known of the transcriptional mechanisms 1994; Zingg et al., 1995) . Arterial and venous SMCs within that regulate smooth muscle cell (SMC)-specific gene exthe vasculature, for example, exhibit distinct properties and are clearly different from the many types of visceral SMCs within the digestive, respiratory, and genitourinary sys-tional diversity of SMCs in many different physiological control gene expression in the skeletal, cardiac, and smooth muscle lineages. processes. Identification of the regulatory mechanisms that
In this study, we show that SM22a transcription is depencontrol gene expression in these distinct SMCs should lead dent on an evolutionarily conserved CArG box in the proto a better understanding at a molecular level of SMC prolifmoter. Although this CArG box binds SRF, SRF alone is eration, differentiation, and determination during eminsufficient for SM22a promoter activation. Rather, our rebryogenesis.
sults suggest that SRF-dependent activation of SM22a tran-We have used the SM22a gene as a marker for elucidating scription requires an additional factor that can be bypassed the mechanisms that regulate muscle gene expression in by fusion of the viral coactivator VP16 to the SRF DNA SMCs. SM22a is a calponin-related protein that is specific binding domain. Our results demonstrate that CArG boxto adult SMCs (Duband et al., 1993) . During mouse embinding factors control SM22a transcription in arterial bryogenesis, SM22a is expressed transiently in the cardiac smooth, skeletal, and cardiac muscle cells and are consisand skeletal muscle lineages before becoming restricted to tent with a model in which SRF acts through a combinato-SMCs during late fetal development (Li et al., 1996a) . Rerial mechanism with a myogenic cofactor(s) to control muscently, we showed that the 445-base-pair promoter of cle gene expression through this site. SM22a was sufficient to direct the expression of a linked reporter gene in the smooth, cardiac, and skeletal muscle lineages of transgenic mice (Li et al., 1996b) . However, in contrast to the endogenous SM22a gene which is expressed
MATERIALS AND METHODS
in all SMC types throughout development, this region of the promoter was active only in a subset of arterial SMCs,
Cloning of the SM22a promoter from chick and human librar-
but not venous nor visceral SMCs. Within the developing ies. Human or chicken SM22a gnomic clones were isolated by heart, this promoter was active only in the bulbus cordis, screening an RPMI8402 human gnomic library (Baer et al., 1988) or CL1012j chicken genomic library (Clonetech, Palo Alto, CA) not in the left ventricle, nor atria (Li et al., 1996b) . These using the 1078-bp mouse SM22a cDNA (Li et al., 1996b) as a probe results have been confirmed by others (Moessler et al., under the following low-stringency conditions. Briefly, the gnomic 1996). The finding that the SM22a promoter directed exlibraries were lifted in duplicate onto nitrocellulose filters that pression to a subset of SMC types, whereas the endogenous were then baked at 80ЊC under vacuum for 2 hr. After prehybridizagene was expressed throughout diverse SMC types, indition for 4 hr at 42ЊC in a solution containing 35% formamide, 51 cated that separate regulatory elements govern SM22a tran-SSC, 51 Denhardt's solution, 0.05 M NaHPO 4 , pH 7.0, 0.1% SDS scription in different SMC types and suggested that different and 100 mg/ml of salmon sperm DNA, the filters were hybridized regulatory programs are utilized to control expression of overnight in similar solution, but with the following modifications, 20% formamide, 10% dextran sulfate, and without SDS. Filters this gene in different tissues during embryogenesis.
were washed in 21 SSC, 0.1% SDS solution twice (20 min each The region of the SM22a promoter that directs expression time), and once in 0.51 SSC, 0.1% SDS at 50ЊC. The filters were in transgenic mice contains two CArG (CC(A/T) 6 GG) then exposed to X-ray films (Kodak) at 070ЊC overnight. Duplicate boxes, which were first identified as important regulatory positive clones were picked for secondary and tertiary screening. elements in the cardiac and skeletal a-actin gene promoters
The sequences for the human and chicken SM22a proximal pro- (Gustafson et al., 1988; Grichnik et al., 1988) . Subsequently, moters were determined using primers from the 5 untranslated CArG boxes were found to be among essential regulatory regions of the corresponding human and chicken cDNA sequences. elements in the promoters of a number of cardiac, skeletal, DNA sequences of both strands were determined by automated sequencing. Sequence alignment was performed using the Genetic and smooth muscle genes (Owens, 1995; Lee et al., 1991;  Computer Group (GCG) software package (University of Texas Miwa et al., 1987; Mohun et al., 1989; Walsh, 1989; Catala Southwestern Medical Center). et al., 1995; Yano et al., 1995; Katoh et Oligonucleotide synthesis and site-directed mutagenesis. al., 1994; Goswami et al., 1994; Argentin et al., 1994;  Oligonucleotides encompassing the CArG-near or CArG-far Amacher et al., 1993; Chow and Schwartz, 1990) . The CArG boxes and 10-15 nucleotides of flanking sequence were synthesized box binds serum response factor (SRF), a member of the by Genosynthesis Inc. (Houston, TX). For convenience, an EcoRI MADS (MCM1, agamous, deficiens, serum response factor) or HindIII site was introduced into the mutant CArG boxes. The box family of transcription factors (Shore and Sharrocks, mutated oligonucleotides were synthesized with 5-phosphorylation and purified on polyacrylamide gels. The sequences of synthe-1995; Treisman and Ammerer, 1992) . SRF is expressed in a sized oligonucleotides were as follows (the CArG boxes are undervariety of muscle and nonmuscle cells (Shore and Sharrocks, lined and the mutated bases are bolded and italized): 1995). However, it is highly restricted to cardiac, skeletal, and smooth muscle lineages during avian embryogenesis CArG-near oligo: 5-AACTTGGTGTCTTTCC (Croissant et al., 1996) . Transcriptional regulation by SRF has been shown to require combinatorial interactions with CCAAATATGGAGCCTGTGTGGAGTG accessory factors (Chow and Schwartz, 1990; Treisman, 1994; Macleod et al., 1992; Hill et al., 1993; Chen and CArG-near-mutant oligo: 5-GGTGTCTTTCC Schwartz, 1996; Grueneberg et al., 1992) raising the possi-CGAATTCTGGAGCC bility that myogenic cofactors may cooperate with SRF to CArG-far oligo: 5-GGTTTCAGGGTCCTGC pSM1343lacZ (Li et al., 1996b) with mutations at the CArG-near or CArG-far box, respectively, were digested with NotI and HindIII CCATAAAAGGTTTTTCCCGGCCGCC to eliminate bacterial vector sequences. The DNA fragments for injection were purified by Qui-quick column and resuspended in CArG-far-mutant oligo: 5-GGGTCCTGC injection buffer (Cheng et al., 1992) . Methods for transgenic mice generation and detection were described previously (Li et al., 1996b; CAATAAAAGCTTTTT Cheng et al., 1992) . To detect the expression of the lacZ transgene, transgenic embryos were isolated at E11.5 and the yolk sacs were The mutants were generated initially in the Bluescript vector, saved to detect transgene integration by Southern analysis or PCR. containing a region of the SM22a promoter extending from the The embryos were fixed in 2% formaldehyde for 30 min and rinsed transcription initiation site to 01343bp, using the Chameleon muwith 11 PBS for 1 hr before staining for b-galactosidase activity. tagenesis kit (Stratagene). To analyze the effects of introduced mu-To better visualize the vasculature of the embryo, stained embryos tations on the SM22a promoters, the mutated promoters were were dehydrated in 100% methanol for 2 days and cleared in a cloned into the same promoterless vectors containing lacZ or lucifsolution of benzyl benzoate and benzyl alcohol (2:1 by volume) for erase as reporters (Li et al., 1996b) .
1-3 hr before photography. For histology, X-gal-stained embryos Transfection and luciferase assay. To determine the transcripwere embeded in paraffin after gradual dehydration in ethanol and tional activities of the mutated SM22a promoters, the rat PAC1 washing in xylene. Embryos were sectioned at 7 mm per section and (pulmonary artery cell) SMC cell line (gift from Dr. S. Schwartz), counterstained with hematoxylin and eosin (Laboratory of Clinical primary SHR rat aortic SMCs, C2 skeletal myoblasts, and F9 cells Pathology, Harper Hospital, Wayne State University). were seeded in 6-cm dishes for transfection. After 24 hr, cells were transfected in 10% fetal bovine serum (FBS) at about 70% confluency except for F9 cells, which were at about 50% confluency. The pSM1343-luc plasmid contains 1343 bp of the SM22a promoter
RESULTS
linked to the luciferase reporter gene (Li et al., 1996a) . In plasmid SRF-VP16, amino acids 411-490 of herpes simplex virus protein, Evolutionary conservation of the SM22a promoter. We VP16, were fused to the N-terminus of full-length SRF (Grueneberg reported previously that the region from 0445 to /62 of et al., 1992) . Both SRF and SRF-VP16 were in pCGN vectors (Tathe mouse SM22a gene was sufficient to direct expression naka et al., 1990) . Then 2.5 to 5 mg of each luciferase reporter of a linked lacZ transgene in a subset of arterial SMCs plasmid was transfected by calcium phosphate precipitation. Briefly, cells were fed with 5 ml 10% FBS 3 hr before transfection. throughout pre-and postnatal development and transiently Plasmid DNA together with 31 ml of 2 M CaCl 2 was brought to a in the cardiac and skeletal muscle lineages during mouse final volume of 250 ml with water and was then added dropwise to embryogenesis (Li et al., 1996b) . To begin to define the cis-FIG. 1. Evolutionary conservation of SM22a promoter sequences. (A) The sequences of the SM22a promoters from mouse, rat, human, and chicken are compared. A dash indicates identity with the mouse sequence. The promoter sequences diverge upstream of 0389 bp of the mouse sequence and the chick promoter sequence diverges from the mammalian promoter sequences downstream of 0104 bp. The CArG-far, CArG-near, and TATA-like sequences are boxed. Sequences from mouse and rat are numbered relative to the transcription initiation site. The transcription initiation site has not been reported for the human or chick genes; nucleotides for these species are therefore unnumbered. GenBank accession numbers for the chick and human sequences are AF009174 and AF009175, respectively. (B) Comparison of CArG-near and surrounding sequences with a homologous region from the mouse SM a-actin promoter. ognize sequences flanking the CArG box, also referred to
We also tested nuclear extracts from a variety of cell lines for binding to the CArG-near and CArG-far regions. Several as the serum response element (SRE) (Hill et al., 1994) .
Binding of SRF to the SM22a promoter. To determine DNA-protein complexes were observed using labeled CArG-near and CArG-far probes with nuclear extracts from whether the CArG boxes in the SM22a promoter could bind SRF, we initially performed gel mobility shift assays using SHR SMCs and C2 skeletal myotubes (Figs. 2B and 2C), both of which support activation of the SM22a promoter. a bacterially expressed GST-SRF fusion protein and 32 Plabeled probes corresponding to the CArG-near and CArG-To test whether SRF was contained in any of these complexes, SRF antibody was included in certain of the binding far boxes and their flanking sequences. SRF bound avidly to both sequences ( Fig. 2A) , yielding a complex with similar reactions. In the presence of the antibody, the slowest migrating complex was supershifted to the top of the gel, indi-mobility to that seen using the c-fos SRE as a probe with GST-SRF or SMC nuclear extracts.
cating that this complex contained SRF (Fig. 2B , lanes 2 and 7; Fig. 2C , lanes 2 and 8). Preimmune serum had no effect sion of a luciferase reporter gene in transfected PAC1 cells and primary SHR aortic SMCs. The 1343 bp promoter in on the SRF-containing complex (not shown). The SRF-containing complex was readily detectable in SMCs and C2 the reporter construct pSM1343-luc was transcriptionally active in PAC1 cells ( Fig. 3 ), as well as in primary SMCs (not myotubes (Fig. 2B, lanes 1 and 6; Fig. 2C, lanes 1 and 7) . In contrast, this complex was barely detectable, if at all, in F9 shown). Mutation of either of the CArG boxes significantly reduced the activity of the promoter, suggesting that both cells (Fig. 2B, lane 8; Fig. 2C , lane 9), in which the SM22a promoter is inactive (Li et al., 1996b) .
CArG boxes are required for full transcriptional activity of the SM22a promoter in tissue culture. The SRF-containing complex was abolished in the presence of unlabeled oligonucleotides corresponding to the c-Differential requirements of CArG-near and CArG-far boxes for SM22a transcription in developing myogenic lin-fos SRE or the CArG-near and CArG-far sequences (Fig. 2B,  lanes 3 and 4; Fig. 2C, lanes 3-5) . In addition to SRF, there eages in vivo. We also investigated the potential importance of the two CArG boxes for SM22a promoter activity appeared to be other factors that bound specifically to the CArG-far and CArG-near probes. The factors involved in in transgenic mice by comparing the expression of a lacZ reporter gene linked to the wild-type 1343-bp promoter or formation of these complexes appeared to be specific for sequences unique to each probe since they were specifically mutant promoters in which each CArG box had been altered. The activity of these constructs was examined in competed by the cognate unlabeled probe, but not by the c-fos SRE or the opposite CArG oligonucleotides (Figs. 2B founder transgenic mice at E11.5. As reported previously (Li et al., 1996b; Moessler et al., 1996) , the SM22a promoter and 2C, compare lane 1 with lanes 3, 4, and 5). This result indicated that there were factors in addition to SRF binding directed transcription in the developing vasculature and heart tube, as well as in skeletal muscle cells of the somite to the flanking sequences of the CArG box regions, which might be involved in regulation of SM22a gene expression. myotome at E11.5 ( Figs. 4A and 4D ). We analyzed four independent transgenic embryos harboring the transgene Both CArG boxes are required for full activity of the SM22a promoter in cultured SMCs. To examine whether SM1343CArG-far-mut-lacZ, in which CArG-far had been mutated; all of the embryos showed expression patterns in the CArG boxes in the SM22a promoter were important for transcription, we mutated each CArG box individually in the arterial vasculature similar to those of embryos harboring the wild-type transgene. This mutant transgene was also the context of the 1343-bp promoter and assayed the abilities of the wild-type and mutant promoters to drive expres-expressed in myotomes of the somites, but expression in vector was not sufficient to activate the promoter in F9 cells, indicating that the lack of SRF expression in these cells cannot by itself account for the failure of the SM22a promoter to be expressed. There are at least two potential mechanisms that could account for the inability of exogenous SRF to activate the SM22a promoter in F9 cells. SRF could be inactive in this cell type, by a block to DNA binding, for example, or F9 cells could lack cofactors required by SRF for SM22a promoter activation. In an attempt to distinguish between these possibilities, we tested whether SRF-VP16, in which the activation domain of the viral protein VP16 was fused to the N-terminus of the full-length SRF (Grueneberg et al., 1992) , could activate the SM22a promoter to in F9 cells. Indeed, SRF-VP16 activated the SM22-luciferase reporter in is lacking in F9 cells.
DISCUSSION
the myotomes was limited to one or two cell layers (Fig.  4B ). Although the lacZ gene was expressed in the bulbus SM22a is expressed in all SMC types throughout pre-and postnatal development and transiently in the cardiac and cordis of the heart at E11.5, expression was not detected in the trabeculae of the myocardium, but was limited to the skeletal muscle lineages during embryogenesis (Li et al., 1996a) . Thus, defining the mechanisms that regulate SM22a wall of the conus arteriosus within the bulbus cordis where the spirally aortic and pulmonary channels were forming transcription should lead to an understanding of the similarities and differences in the regulatory programs for muscle ( Figs. 4B and 4E ). Among these four transgenic embryos, there was only one that showed additional ectopic expres-gene expression in these different muscle cell types. The ability of the proximal SM22a promoter to direct transcrip-sion in the apical ectodermal regions of the limbs. Because we have never seen this ectopic expression pattern in other tion specifically in arterial but not in venous nor visceral SMCs also provides an opportunity to define the regulatory embryos, we believe that it reflects a positional effect of transgene integration.
programs that distinguish these different types of SMCs.
Regulation of SM22a transcription by CArG box-bind-
In contrast to the apparently normal expression pattern of the CArG-far-mutant promoter in vascular SMCs, we ing factors. Our results demonstrate that activation of SM22a transcription by SRF is mediated by two evolution-never observed expression of the transgene SM1343CArGnear-mut-lacZ, in which CArG-near was altered, in any arily conserved CArG boxes in the SM22a promoter. Whereas both sites are important for transcriptional activa-muscle cell lineage (Fig. 4C) . A total of 16 embryos were shown to be positive for transgene integration by both PCR tion of the gene in cultured SMCs, they contribute differently to the temporospatial expression pattern of the SM22a and Southern analysis. In only one embryo with this transgene did we observe ectopic expression of lacZ in the promoter in transgenic mice. While the proximal CArG box, CArG-near, appears to be essential for SM22a expression in forebrain (not shown). These results demonstrate that the two CArG boxes in the SM22a promoter play distinct roles smooth, skeletal, and cardiac muscle cells, the distal CArG box, CArG-far, is important for the expression in the myo-in the control of SM22a transcription in vivo and they reveal an important role for SRF (or other CArG box-binding cardium of the bulbus cordis and in the myotome. These results reveal distinct roles of the two SM22a CArG boxes factors) in the control of SM22a transcription in developing skeletal, cardiac, and smooth muscle cell lineages. in governing gene expression in different regions of the embryo. Since mutations that abolish binding of SRF to the SRF alone is insufficient for activation of the SM22a promoter. To investigate whether SRF was sufficient to acti-SM22a CArG boxes result in altered promoter activity, we favor the conclusion that SRF is a key regulator of the gene vate the SM22a promoter, we tested whether expression of SRF in F9 cells would lead to activation of an SM22a-luciferin different myogenic lineages. The differential requirements of the two CarG boxes in different myogenic lineages ase reporter gene containing the 2763-bp SM22a promoter. As shown in Fig. 5 , cotransfection of an SRF expression could reflect the association of SRF with different cofactors. and smooth muscle cell lineages during embryogenesis (Croissant et al., 1996; R. Schwartz, personal communication) . However, the SM22a promoter is active in only a subset of myogenic cells in which SRF is expressed. The SM22a promoter is expressed transiently in skeletal muscle cells in the myotome, whereas SRF continues to be expressed in differentiating skeletal muscle (Croissant et al., 1996) . Similarily, the SM22a promoter is active only transiently in the bulbus cordis (the future right ventricle), but not in the left ventricular region of the heart, whereas SRF has been shown to be expressed throughout the developing heart during avian embryogenesis (Croissant et al., 1996) . This apparent disparity between SRF expression and SM22a promoter activity indicates that SRF is not sufficient for SM22a activity. Moreover, since SRF is not strictly musclespecific, it alone cannot account for the highly specific expression pattern of the SM22a promoter. We therefore favor there could be a common myogenic cofactor for SRF that pression vectors encoding either SRF or SRF-VP16. Two days after is expressed in multiple muscle cell types.
transfection, cells were harvested and luciferase activities were determined. The results represent the averages of duplicate transfec-
Evidence for SRF cofactors in the regulation of SM22a
tions and are expressed as the level of expression relative to luc.
transcription. The SM22a promoter was transcriptionally
Values did not vary by more than 10% of the mean. The SV40 silent in F9 cells, which express very low levels of SRF.
promoter in pSV-luc is expressed at a low level in F9 cells and is Forced expression of SRF in F9 cells failed to activate a not responsive to SRF-VP16.
reporter gene linked to the SM22a promoter, which demonstrates that SRF alone cannot account for cell-type-specific activity of the SM22a promoter. However, an SRF-VP16 fusion protein can activate the SM22a promoter in trans-However, it is formally possible that another as yet unidentified factor acts through the CArG boxes independent of fected F9 cells. These results demonstrate that SRF is capable of binding the CArG box in F9 cells and they suggest SRF. SRF, binding to both CArG-far and CArG-near boxes, might therefore interact with different accessory factors to that an additional cell-type-restricted factor that is lacking in F9 cells is required for SRF-dependent activation of the activate transcription in different myogenic lineages.
CArG boxes have also been shown to play important roles SM22a promoter. Apparently, the strong activation domain of VP16 (Grueneberg et al., 1992) can bypass the require-in regulation of many smooth, cardiac, and skeletal muscle genes in cultured cells (Owens, 1995; Lee et al., 1991; Miwa ment for this coactivator. The possibility that SRF cooperates with other tissue-and Kedes, 1987; Mohun et al., 1989; Walsh, 1989; Catala et al., 1995; Yano et al., 1995; Katoh et restricted cofactors to control muscle gene expression is consistent with the mechanism by which SRF confers se-al., 1994; Goswami et al., 1994; Argentin et al., 1994; Amacher et al., 1993; Chow and Schwartz, 1990) , but few rum-inducibility to the c-fos promoter. In that case, SRF has been shown to act in combination with other accessory studies have examined the contributions of CArG boxes to muscle gene activation during embryogenesis. The SM afactors, referred to as ternary complex factors (TCFs), that recognize sequences adjacent to the SRE (Hill and Treisman, actin promoter contains two CArG boxes that are required for transcriptional activity in cultured SMCs (Shimizu et 1995; Hipskind and Nordheim, 1991) . TCFs, which belong to the ets family of transcription factors, fail to bind these al Sun et al., 1995; Cogan et al., 1995) . The promoters of the smooth muscle myosin heavy chain (Katoh et al., flanking sequences alone, but in the presence of SRF they make specific DNA contacts with a site immediately adja-1994) and caldesmon (Yano et al., 1995) genes, which are expressed specifically in SMCs, also contain CArG boxes, cent to the SRE (Price et al., 1995; Treisman and Ammerer, 1992; Dalton et al., 1993) . It is interesting to note that there but their potential roles in regulation of these genes have not yet been examined. CArG boxes have also been shown is a consensus binding site for Ets proteins, GGA(A/T), immediately adjacent to the proximal SM22a CArG box. The to be important for transcription of the a-cardiac and askeletal actin genes in culture (Gustafson et al., 1988; Shore MADS domain of SRF also interacts with the homeodomain protein Phox/MHox , which is ex-and Sharrocks, 1995).
How might SRF regulate SM22a transcription? SRF is pressed at high levels in muscle cells .
Recent studies have shown that the cardiac homeodomain expressed at high levels in cultured SMCs (Shimizu et al., 1995;  and this study) and in developing skeletal, cardiac, protein Nkx-2.5 also interacts with the MADS domain of SRF, resulting in cooperative transcriptional activation (Lilly et al., 1995) . These findings have led to the conclusion that MEF2 is an essential component of the regulatory pro- (Chen and Schwartz, 1996) . SRF has also been shown to interact with members of the MyoD family of skeletal-mus-grams that control differentiation of muscle cells from multiple lineages. The SM22a promoter does not contain a con-cle-specific basic helix-loop-helix (bHLH) proteins (Groisman et al., 1996) . sensus MEF2 site. However, recent studies have revealed that the SM22a is not expressed in the vasculature of There is also evidence for factors that interfere with the activity of SRF. Activation of the a-skeletal actin promoter MEF2C-null embryos (Q. Lin, J. Schwarz, and E. Olson, unpublished) , suggesting that MEF2C may regulate this pro-by SRF, for example, is inhibited by the transcription factor YY1, which binds a site overlapping the CArG box (Lee et moter through an indirect pathway. Such regulation could occur through the association of MEF2C with other SM22a al., 1994) . In undifferentiated skeletal myoblasts, in which YY1 is expressed at high levels, SRF is precluded from bind-promoter-binding factors or it could be mediated by other myogenic factors that are regulated by MEF2C. ing to the promoter, whereas following initiation of differentiation, YY1 is downregulated, thereby allowing SRF ac-Multiplicity of SMC transcriptional regulatory programs. Dissection of the SM22a promoter has revealed cess to its binding site (Lee et al., 1994) . In the SM22a promoter, YY1 can bind to the CArG-near, but not the unexpected diversity in the regulatory mechanisms that control SMC gene expression. While we have identified the CArG-far, region (L. Li, unpublished observations al., 1996a; Ruzicka and Schwartz, 1988) . This may indicate that the contractile and electrophysiolog-hypertension (Schwartz et al., 1995) . SM22a appears to respond to stimuli that modulate SMC proliferation because ical properties of cardiac and skeletal muscle cells resemble those of SMCs early in development. Indeed, the primative SM22a expression is detected in differentiated arterial SMCs within the tunica media, but not within proliferative cardiac tube, which expresses smooth muscle genes, resembles a vessel.
SMCs within atherosclerotic plaques. Further analysis of the regulation of this promoter should yield insights into Members of the MyoD family of bHLH proteins activate gene expression in the skeletal muscle lineage by binding the regulatory mechanisms that modulate SMC phenotypes and should reveal the mechanisms that specify the identi-the E box consensus sequence in the control regions of muscle-specific genes (Weintraub et al., 1994; Olson, 1990) .
ties of different SMC types. There are no E boxes in the region of the SM22a promoter that directs expression in the myotome. Thus, this muscle gene is not a direct target for transcriptional activation by ACKNOWLEDGMENTS the myogenic bHLH factors. However, there are several examples in which myogenic bHLH proteins activate muscle
We are grateful to M. Parmacek for sharing unpublished results, genes lacking E boxes (Parmacek et al., 1994; to R. Schwartz and S. Schwartz for valuble reagents, to T. L'Ecuyer and H. Maisel for helpful discussion, to A. Tizenor for assistance al., 1995) . The ability of SRF to interact with myogenic with graphics, and to members of the Olson lab for helpful com-bHLH factors could also contribute to expression of SM22a ments. Portions of this work were performed while L.L was at the in the skeletal muscle lineage (Groisman et al., 1996) . How- have been shown to control muscle gene expression in skeletal, cardiac, and smooth muscle cells (Molkentin et al., 1996) . There are four MEF2 genes in vertebrate species,
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